Interpace Diag Group (IDXG)

$1.40 -0.12 (-8.14%)
Market Cap 6.19M
Revenue (ttm) 46.93M
Net Income (ttm) 6.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 14.28%
Debt to Equity Ratio 0.00
Volume 3,400
Avg Vol 11,090
Day's Range N/A - N/A
Shares Out 4.42M
Stochastic %K 67%
Beta 1.06
Analysts Strong Buy
Price Target $11.00

Company Profile

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis of pancreaticobiliary cancers using its proprietary PathFinderTG platform; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 855 776 6419
Address:
Waterview Plaza, Suite 310 2001 Route 46, Parsippany, United States
Esau815
Esau815 Dec. 11 at 3:48 AM
$IDXG Reminder to those unfamiliar with IDXG's cap table. Though the PE Preferred shareholders gave up their preference in 2024, they still can convert to 23MM shares--there are really 27MM shares outstanding. Not 4MM. In terms of valuation based on FCF or EBITDA. Ten times EBITDA gets you a MC of $50MM but ten times cash flow is $70MM or so now that the debt is paid. That gets you $2-$3 per share. You can't get to $20 per share with 27MM shares oustanding under any fantasy scenario.
0 · Reply
doylebery
doylebery Dec. 10 at 5:11 PM
$IDXG
0 · Reply
davidb1010
davidb1010 Dec. 10 at 2:18 AM
$IDXG $IDXG My average price still $17 1.2k shares 😂
1 · Reply
Gojilla24
Gojilla24 Dec. 9 at 11:45 PM
$IDXG nice to see this finally showing some signs of life.
0 · Reply
Esau815
Esau815 Dec. 9 at 12:44 AM
$IDXG WIth all due respect to Waters. There is no way no how that this valuation goes anywhere close to $8. Think you have overlooked that the preferred shares are 81% of the cap table and that the 4MM shares are the 19%. There are 27MM diluted shares outstanding--not 4MM. To have an $8 shares you would need a market cap north of $200MM. Realistically? Even at 10 EBITDA (very generous) you would need EBITDA of $20MM. Maybe if we had PancraGen and still had original reimbursement for thyroid we'd get close. But we're at $5MM EBITDA.
2 · Reply
Esau815
Esau815 Dec. 8 at 4:22 PM
$IDXG First of all--want to shout from the rooftops that I don't have any material non public information. But it's sure trading like someone knows that a deal is imminent. 25k shares on IDXG? That's a millisecond volume in AAPL but an enormous amount for IDXG. There's no shares to be found. Let's see if they get that $2 share price.
1 · Reply
Esau815
Esau815 Dec. 7 at 12:34 AM
$IDXG Think we can get to a sales price of $2.00 a share which is what the preferred shares gave up their preference. (When the stock was $2.85.) REMEMBER. CAUTION. There are 27MM shares outstanding--not 4MM. The preferred gave up their preference but still will get 23MM shares or so when they convert. With the demise of PancraGen it's a bit tricky to figure out what thyroid alone does. It appears that they ma $911 k in Q3. Know you can't extapolate that to cash flow but let's say it's in the ball park. Now. Add $500K per month committed to principal and interest payments. Let's add a bit of growth and I think you can get to close to $1MM per month. 27MM shares. Need $54MM market cap. Figure roughly $12MM FCF. 4.5 times FCF seems to me a reasonable multiple. Even tiny diagnostics get 6. They might need a quarter or two as a "show me stock"
0 · Reply
Esau815
Esau815 Dec. 6 at 12:32 PM
$IDXG Let's give credit to a strong management team that was dealt some very bad cards out of their control. That $12MM debt coupled with the (then) imminent demise of PancraGen would have killed many a company. Their fight of the reimbursement caused about a 2 year delay which lasted long enough to pare down 80% of the debt and they were able to eke out the last 20% by the skin of their teeth. A debt free IDXG will now generate about $500K in FCF. Hopefully, this will be sufficient for the two PE's who own 81% of the company to find a suitable suitor. Ten times cash flow would equate to a little north of $2 per share. This happened to be the price at which they converted. Think that all involved would like to move on.
1 · Reply
Zapp
Zapp Dec. 4 at 1:22 AM
$IDXG great news re: early payoff of 2021 BroadOak debt. Time for a 🚀
0 · Reply
davoid57
davoid57 Dec. 3 at 8:48 PM
$IDXG 2/2 With this debt retired, we have strengthened our balance sheet, positioning us to focus our full resources on driving commercial growth as we continue to deliver record testing volumes and revenue for our thyroid tests.”
0 · Reply
Latest News on IDXG
No data available.
Esau815
Esau815 Dec. 11 at 3:48 AM
$IDXG Reminder to those unfamiliar with IDXG's cap table. Though the PE Preferred shareholders gave up their preference in 2024, they still can convert to 23MM shares--there are really 27MM shares outstanding. Not 4MM. In terms of valuation based on FCF or EBITDA. Ten times EBITDA gets you a MC of $50MM but ten times cash flow is $70MM or so now that the debt is paid. That gets you $2-$3 per share. You can't get to $20 per share with 27MM shares oustanding under any fantasy scenario.
0 · Reply
doylebery
doylebery Dec. 10 at 5:11 PM
$IDXG
0 · Reply
davidb1010
davidb1010 Dec. 10 at 2:18 AM
$IDXG $IDXG My average price still $17 1.2k shares 😂
1 · Reply
Gojilla24
Gojilla24 Dec. 9 at 11:45 PM
$IDXG nice to see this finally showing some signs of life.
0 · Reply
Esau815
Esau815 Dec. 9 at 12:44 AM
$IDXG WIth all due respect to Waters. There is no way no how that this valuation goes anywhere close to $8. Think you have overlooked that the preferred shares are 81% of the cap table and that the 4MM shares are the 19%. There are 27MM diluted shares outstanding--not 4MM. To have an $8 shares you would need a market cap north of $200MM. Realistically? Even at 10 EBITDA (very generous) you would need EBITDA of $20MM. Maybe if we had PancraGen and still had original reimbursement for thyroid we'd get close. But we're at $5MM EBITDA.
2 · Reply
Esau815
Esau815 Dec. 8 at 4:22 PM
$IDXG First of all--want to shout from the rooftops that I don't have any material non public information. But it's sure trading like someone knows that a deal is imminent. 25k shares on IDXG? That's a millisecond volume in AAPL but an enormous amount for IDXG. There's no shares to be found. Let's see if they get that $2 share price.
1 · Reply
Esau815
Esau815 Dec. 7 at 12:34 AM
$IDXG Think we can get to a sales price of $2.00 a share which is what the preferred shares gave up their preference. (When the stock was $2.85.) REMEMBER. CAUTION. There are 27MM shares outstanding--not 4MM. The preferred gave up their preference but still will get 23MM shares or so when they convert. With the demise of PancraGen it's a bit tricky to figure out what thyroid alone does. It appears that they ma $911 k in Q3. Know you can't extapolate that to cash flow but let's say it's in the ball park. Now. Add $500K per month committed to principal and interest payments. Let's add a bit of growth and I think you can get to close to $1MM per month. 27MM shares. Need $54MM market cap. Figure roughly $12MM FCF. 4.5 times FCF seems to me a reasonable multiple. Even tiny diagnostics get 6. They might need a quarter or two as a "show me stock"
0 · Reply
Esau815
Esau815 Dec. 6 at 12:32 PM
$IDXG Let's give credit to a strong management team that was dealt some very bad cards out of their control. That $12MM debt coupled with the (then) imminent demise of PancraGen would have killed many a company. Their fight of the reimbursement caused about a 2 year delay which lasted long enough to pare down 80% of the debt and they were able to eke out the last 20% by the skin of their teeth. A debt free IDXG will now generate about $500K in FCF. Hopefully, this will be sufficient for the two PE's who own 81% of the company to find a suitable suitor. Ten times cash flow would equate to a little north of $2 per share. This happened to be the price at which they converted. Think that all involved would like to move on.
1 · Reply
Zapp
Zapp Dec. 4 at 1:22 AM
$IDXG great news re: early payoff of 2021 BroadOak debt. Time for a 🚀
0 · Reply
davoid57
davoid57 Dec. 3 at 8:48 PM
$IDXG 2/2 With this debt retired, we have strengthened our balance sheet, positioning us to focus our full resources on driving commercial growth as we continue to deliver record testing volumes and revenue for our thyroid tests.”
0 · Reply
davoid57
davoid57 Dec. 3 at 8:48 PM
$IDXG PARSIPPANY, NJ , Dec. 03, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCID: IDXG) (“Interpace” or the “Company”) today announced that it has fully repaid its outstanding term loan facility with BroadOak Capital Partners (“BroadOak”) prior to the facility’s maturity date. The repayment satisfies the Company’s obligations under the Loan and Security Agreement originally entered into on October 29, 2021 , with BroadOak Fund V, L.P. By retiring this debt early, Interpace eliminates related interest expenses, providing increased operational flexibility to support future growth. “The early repayment of the BroadOak facility is a significant milestone for Interpace and a testament to our robust financial performance and disciplined capital management,” said Chris McCarthy , Chief Financial Officer. “Over the past several years, BroadOak has been a valuable partner, supporting our strategic turnaround and transition to profitability.
0 · Reply
Waters59
Waters59 Dec. 2 at 2:53 PM
$IDXG Let's Go!! 📈 Pick up those cheap shares!
0 · Reply
Waters59
Waters59 Nov. 25 at 1:25 PM
$IDXG Time for a reversal! 🚀
0 · Reply
Esau815
Esau815 Nov. 13 at 1:36 PM
$IDXG Agreed. More than respectable quarter. Believe that the plan is to be DONE with the debt by year end. Almost miraculoulous that they were able to stall PancraGen's demise by 18 months to get that debt paid off AND to heave Preferred's convert. Let's see if they can sell this as a debt free company with $35MM in revenues and positive EBITDA. Elimination of interest and debt outstanding will immensely help with cash flow going into 2026.
0 · Reply
Waters59
Waters59 Nov. 12 at 9:39 PM
$IDXG The results were actuall good considering this is the first full quarter of the Company being a Thyroid-only diagnostics testing company. https://www.interpace.com/news-media/press-releases/detail/245/interpace-biosciences-announces-third-quarter-2025
0 · Reply
apppro
apppro Nov. 12 at 9:18 PM
$IDXG OK they just reported. OK not out of business, but not good either.
0 · Reply
Waters59
Waters59 Nov. 12 at 2:46 PM
$IDXG Let's Go! 🚀
0 · Reply
apppro
apppro Nov. 10 at 4:44 PM
$IDXG when do these idiots report?? I have on calender today but who the F knows anymore
0 · Reply
Waters59
Waters59 Nov. 10 at 4:38 PM
$IDXG
0 · Reply
Waters59
Waters59 Nov. 3 at 8:00 PM
$IDXG Don't let this go back down. Chug-a-lug! 🚀
0 · Reply
Waters59
Waters59 Oct. 31 at 3:01 PM
$IDXG Eat those shares! Gobble gobble. Let's Go! 🚀
0 · Reply
crane_train21
crane_train21 Oct. 30 at 11:00 PM
$IDXG I dumped shares and it bumped immediately lmao
1 · Reply